In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Selina M. Luger argues that hypomethylating agents should be used with caution in lower-risk patients with myelodysplastic syndromes (MDS).
A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204
© 2016 Imedex, LLC.
Advertisement